ERYTECH to Host KOL Breakfast Symposium with Audio Webcast on November 7, 2018
The event will feature four guest speakers, who will highlight the treatment landscape and unmet medical need in pancreatic and triple negative breast cancers, and zoom in on the evolving field of cancer metabolism:
- Prof. Dr.
Ahmed Awada , Head of theOncology Medicine Department at theJules Bordet Institute ,Brussels, Belgium - Prof. Dr.
Javier Cortes , Head of the Breast Cancer Program, Ramon yCajal University Hospital ,Madrid, Spain - Prof. Dr.
Pascal Hammel , Head of the Digestive Oncology unit atBeaujon Hospital ,Paris VII University ,Paris, France - Prof. Dr.
Manuel Hidalgo Medina , Chief of Hematology/Oncology Division atBeth Israel Deaconess Medical Center ,Boston, MA , United States
Members of ERYTECH management will provide an overview of the company’s technology and clinical pipeline.
Webcast Information
A live audio webcast of the KOL breakfast and replay will be available online from the Investors section of ERYTECH’s website at www.erytech.com. A replay of the presentation will be accessible on the ERYTECH website for 30 days following the presentation.
About ERYTECH and eryaspase: www.erytech.com
ERYTECH is a clinical-stage biopharma company developing innovative red blood cell-based therapeutics for cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates to address markets with high unmet medical needs.
ERYTECH’s prime focus is on the development of products that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH’s next product candidate erymethionase, methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers, has demonstrated promising preclinical results and is being prepared to enter Phase 1 clinical development.
ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme therapies (ERYZYME).
ERYTECH produces product candidates at its GMP-approved and operational manufacturing site in Lyon,
ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
CONTACTS
ERYTECH Eric Soyer CFO/COO |
NewCap Mathilde Bohin / Louis-Victor Delouvrier Investor relations Nicolas Merigeau Media relations |
+33 4 78 74 44 38 investors@erytech.com |
+33 1 44 71 98 52 erytech@newcap.eu |
Forward-looking information
This press release contains forward-looking statements, forecasts and estimates with respect to the clinical results from and the development plans of eryaspase, business and regulatory strategy, expansion of manufacturing capacity and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. All statements contained in this press release other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the potential of ERYTECH’s product pipeline, its clinical development and regulatory plans for eryaspase, the timing of ERYTECH’s clinical studies and trials and announcements of data from those studies and trials, and the contents and timing of decisions by the
Source: Erytech Pharma S.A.